United Therapeutics scores FDA go-ahead for pig organ transplant clinical trial
United Therapeutics has scored a regulatory green light to start clinical trials for its genetically modified pig kidneys to ...
United Therapeutics price target lowered to $460 from $475 at UBS
UBS lowered the firm’s price target on United Therapeutics (UTHR) to $460 from $475 and keeps a Buy rating on the shares. United Therapeutics ...
Experimental transplants with organs from gene-edited pigs see major steps forward
On Friday, doctors at Massachusetts General Hospital announced that a 66-year-old New Hampshire man had successfully received a pig kidney transplant.
NH man is 2nd person known to be living with a pig kidney after Mass. General Hospital transplant
A New Hampshire man fought for the chance at a pig kidney transplant, spending months getting into good enough shape to be ...
United Therapeutics: TETON 1 study of nebulized Tyvaso for IPF fully enrolled
United Therapeutics (UTHR) announced full enrollment of the TETON 1 study evaluating the use of Tyvaso or treprostinil, inhalation solution or ...
STAT4d
FDA approves first xenotransplantation clinical trial, as United Therapeutics forges ahead
United Therapeutics said the FDA has cleared it to begin the first clinical trial testing whether organs from gene-edited ...
FDA Greenlights Studies of Pig Kidney Transplants in Humans
The US Food and Drug Administration approved clinical trials that will transplant organs from genetically modified pigs into ...
United Therapeutics president sells $3.5m in stock
Michael Benkowitz, President and COO of United Therapeutics Corp (NASDAQ:UTHR), recently executed a series of stock transactions, according to a recent SEC filing. On February 3, Benkowitz sold shares ...
FDA approves United Therapeutics' xeno-organ trial
Corporation (NASDAQ: UTHR) has received clearance from the U.S. Food and Drug Administration (FDA) to begin a pioneering clinical trial of its gene-edited xenotransplantation kidney, named UKidney, ...